Trials / No Longer Available
No Longer AvailableNCT01980732
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Andrei Iagaru · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-DOTA TATE | Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging. |
Timeline
- First posted
- 2013-11-11
- Last updated
- 2017-08-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01980732. Inclusion in this directory is not an endorsement.